Venlafaxine and nefazodone, two pharmacologically distinct antidepressants

Pharmacotherapy

Volumn 17, Issue 3, 1997, Pages 511-530

  Augustin, Bruce G ^a   Cold, Julie A ^a   Jann, Michael W ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG RECEPTOR BINDING; HEADACHE; HUMAN; NAUSEA; REVIEW; SOMNOLENCE; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TRIAZOLES;

EID: 0030950268     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Depression Guideline Panel. Depression in primary care, vols 1 and 2. Rockville, MD: U.S. Department of Health and Huhumans Services, Public Health Service Agency for Health Care Policy and Research, 1993.
2. Greenberg PE, Stiglin LE, Finkelstein SN, et al. Depression: a neglected major illness. J Clin Psychiatry 1993;54:419-24.
3. Grimsley SR, Jann MW. Paroxetine, sertraline and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-57.
4. Laird LK, Benefield WH. Mood disorders. In: Young LY, Koda-Kimble MA, eds. Major depressive disorders. Vancouver, WA: Applied Therapeutics,1995:76-1-76-28.
5. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy 45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
6. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological and behavioral effects of Wy 45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9.
7. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-15.
8. Bolden-Watson C, Richelson E. Blockade of newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-9.
9. Holliday SM, Benefield P. Venlafaxine. Drugs 1995;49:280-94.
10. Saletu B, Grunberger J, Anderer P, et al. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 1992;33:589-601.
11. Scott JA, Crews FT. Down regulation of serotonin but not beta-adrenergic receptors during chronic amitriptyline treatment is independent of serotonin and β-receptor stimulation. Neuropharmacology 1986;25:1301-6.
12. Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 1994;55:479-83.
13. Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 1993;16(suppl 3):S45-50.
14. Aghajanian GK, Cedarbaum JM, Way RY. Evidence for norepinephrine mediated collateral inhibition of locus ceruleus neuron. Brain Res 1977;136:570-7.
15. Nyback H, Walter JR, Aghajanian GK, Roth RH. Tricyclic antidepressants: effects on the firing rate of brain norepinephrine neurons. Eur J Pharmacol 1975;32:302-7.
16. Haskins JT, Moyer JA, Muth EA, et al. DMI, Wy 45,233, Wy 45,881, and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol 1985;115:139-46.
17. Semlitsch HV, Anderer P, Saletu B, et al. Acute effects of novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate, and mood in young healthy subjects. Int Clin Psychopharmacol 1993;8:155-66.
18. Mitchell PJ, Fletcher A. Venlafaxine exhibits preclinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology 1993;32:1001-9.
19. Wilner P. Animal models of depression. An overview. Pharmacol Ther 1990;45:425-55.
20. Pick CG, Paul D, Eison M, Pasternak GW. Potentiation of opioid analgesia by the antidepressant nefazodone. Eur J Pharmacol 1992;211:375-81.
21. Claudia DB, Gregor L, Thomas B, Clemenz H, Ulrich V. Influences of venlafaxine on growth hormone, and other hormones in healthy subjects. Neuropsychopharmacology 1993;9(2suppl):100S-1.
22. Walsh AES, Cowen PJ. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 1994;14:268-73.
23. Jacobs BL. Serotonin, motor activity and depression-related disorders. Am Sci 1994;82:456-63.
24. Nierenberg AA, Adler LA, Peslow E, Zornberg G, Resenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-72.
25. Sharply AL, Walsh AES, Cowen PJ. Nefazodone - a novel antidepressant may increase REM sleep. Biol Psychiatry 1992;31:1070-3.
26. Ware JC, Rose FV, McBrayer RH. The acute effects of nefazodone, trazodone, and buspirone, on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994;17:544-50.
27. Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clin Pharm 1982;1:406-17.
28. Saenz de Tejada I, Ware JC, Blanco R, et al. Pathophysiology of prolonged penile erection associated with trazodone. J Urol 1991;145:60-4.
29. Armitage R, Rush AJ, Trivedi M, et al. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994;10:123-7.
30. Hicks D, Wolaniuk D, Russell A, et al. A high-performance liquid chromatography method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit 1994;16:100-7.
31. Franc JE, Duncan GF, Farmen RH, et al. High-performance liquid chromatography method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr 1991;570:129-38.
32. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995;29:387-95.
33. Klamerus KJ, Maloney K, Rudolph R, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-24.
34. Sisenwine SF, Politowski J, Birk L, et al. A prefactory investigation of the metabolic disposition of Wy 45,030 in humans. Acta Pharmacol Toxicol 1986;59(suppl 5):312.
35. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994;51:3033-46.
36. Wang CP, Howell SR, Scatina J, et al. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 1992;4:84-90.
37. Troy SM, Parker VD, Fruncillo RJ, et al. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995;35:404-9.
38. Howell SR, Husbands GEM, Scatina JA, et al. Metabolic disposition of C14 venlafaxine in mouse, rat, dog, rhesus monkey and humans. Xenobiotica 1993;23:349-59.
39. Sellers EM, Ball SE, Chueng SW, et al. Inhibition by venlafaxine and other 5-HT uptake inhibitors of the polymorphic enzyme CYP 2D6 [abstr]. Nashville, TN: American College of Neuropsychopharmacology, 1993:163.
40. Otton SV, Ball SE, Chueng SW, Inaba T, Sellars EM. Comparative inhibition of the polymorphic enzyme CYP 2D6 by venlafaxine and 5HT uptake inhibitors. Clin Pharmacol Ther 1994;55:141.
41. Fogelhumans S, Schmider J, Greenblatt DJ, Shader RI. Metabolism of venlafaxine: the role of P450 isoforms. J Clin Pharmacol 1995;35:936.
42. Otton SV, Ball SE, Chueng SW, Inaba T, Rudolph RL, Sellars EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-56.
43. 14 nefazodone in the dog. Drug Metab Dispos 1993;21:502-7.
44. Bristol-Myers Squibb. Serzone (nefazodone) package insert. Princeton, NJ; 1995.
45. Dolpheide JA, Stimmel GL, Yi DD. Focus on nefazodone. Hosp Formulary 1995;30:205-12.
46. Mayol RF, Cole CA, Luke GM, et al. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994;22:304-11.
47. Melzackaps M, Boksa J, Mai J. 1-m-CPP, a metabolite of trazodone isolated from rat urine. J Pharm Pharmacol 1979;31:855-6.
48. Shukla U, Shea JP, Gamhumanss RE. Single and multiple dose pharmacokinetics of nefazodone and two metabolites in healthy volunteers. Clin Pharmacol Ther 1987;41:205.
49. Kaul S, Shukla U, Barbhaiya RH. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995;35:830-9.
50. Barbhaiya RH, Marathe PH, Greene DS, et al. Safety, tolerance and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind phase I study. J Clin Pharmacol 1995;35:974-84.
51. Buch A, Shukla U, Pitthumans K, et al. Pharmacokinetics of nefazodone in extensive and poor metabolizers of dextromethorphan. Pharm Res 1993;10:S314.
52. DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994;97(suppl 6A):13S-23.
53. Von Moltke LL, Greenblatt DJ, Schneider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):33-44.
54. Greenblatt DJ, Von Moltke LL, Harmartz JS, et al. Alprazolam pharmacokinetics, metabolism and serum concentrations. Clinical implications. J Clin Psychiatry 1993;54(suppl 10):4-11.
55. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo M, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin reuptake inhibitors, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
56. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo M, et al. Inhibition of desipramine hydroxylation in vitro by serotonin reuptake inhibitor antidepressants and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
57. Schmider J, Greenblatt DJ, Von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996;41:339-43.
58. Parker V, Pruitt L, Maloney K, et al. Effects of age and sex on the pharmacokinetics of venlafaxine. J Clin Pharmacol 1990;30:832.
59. Wyeth-Ayerst, Inc. Effexor (venlafaxine) package insert. Princeton, NJ; 1994.
60. Troy SM, Schultz RW, Parker VD, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994;56:14-21.
61. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996;16:19-25.
62. Barbhaiya RH, Shukla UA, Natarajan CS, et al. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 1995;58:390-8.
63. Troy SM, Parker VD, Hicks DR, Boudinot FD, Chiang ST. Pharmacokinetic interaction between multiple dose venlafaxine and single dose lithium. J Clin Pharmacol 1996;36:175-81.
64. Troy SM, Lucki I, Peirgies AA, et al. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995;35:410-19.
65. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16:37s-53.
66. Shader RI, Von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996;16:197-201.
67. Greene DS, Dockens RC, Salazar DE, et al. Coadministration of nefazodone and benzodiazepines. I. Pharmacokinetic assessment. Clin Pharmacol Ther 1994;55:141.
68. Kroboth P, Folan M, Lush R, et al. Coadministration of nefazodone and benzodiazepines. II. Pharmacodynamic assessment. Clin Pharmacol Ther 1994;55:142.
69. Honig PH, Wotham DC, Zahumansi K, et al. Terfenadine-ketoconazole interaction. JAMA 1993;269:1513-18.
70. Zechnichi AD, Hedges JR, Eiselt-Proteau D, et al. Possible interactions with terfenadine or astemizole. West J Med 1994;160:321-5.
71. Barbhaiya RH, Shukla UA, Greene DS. Lack of interaction between nefazodone and cimetidine: a steady-state pharmacokinetic study in humans. Br J Clin Pharmacol 1995;40:161-5.
72. Frewer LJ, Lader M. The effects of nefazodone, imipramine, and placebo, alone and combined with alcohol in normal subjects. Int Clin Psychopharmacol 1993;8:13-20.
73. Barbhaiya RH, Shukla UA, Greene DS, Breuel HP, Midha KK. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 1996;16:26-34.
74. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35:730-8.
75. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-12.
76. Khan A, Labre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27:141-4.
77. Schweizer E, Weise C, Clary C, et al. Placebo controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-6.
78. Mendels J, Johnston R, Mattes J, et al. Efficacy and safety of BID doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-74.
79. Wyeth-Ayerst Labratories. Effexor clinical trial 203. Effexor profile. Princeton, NJ: Author, 1994.
80. D'Amico MF, Roberts DL, Robinson DS, et al. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacol Bull 1990;26:147-50.
81. Cunningham LA, Borison RL, Carhumans JS, et al. A comparison of venlafaxine, trazodone and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
82. Schweizer E, Feighner J, Mandos LA, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
83. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43.
84. Feighner JP, Pambakian R, Fowler, RC, et al. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-21.
85. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164:802-5.
86. Van Moffaert M, Pregaldien JL, Von Frenckell, Gammans R. A double-blind comparison of nefazodone and imipramine in the treatment of depressed patients. New Trends Exp Clin Psychiatry 1994;10:85-7.
87. Fontaine R, Ontveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine and placebo in major depression. J Clin Psychiatry 1994;55:234-41.
88. Anonymous. Nefazodone for depression. Med Lett 1995;37:33-4.
89. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;54(suppl 9):62-8.
90. American Pharmaceutical Association. Special report: therapeutic options in the treatment of depression. Washington, DC: American Pharmaceutical Association, 1994.
91. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific second-generation antidepressant. Pharmacotherapy 1987;1:1-15.